126 related articles for article (PubMed ID: 34047516)
1. Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients.
Gening SO; Abakumova TV; Antoneeva II; Rizvanov AA; Gening TP; Gafurbaeva DU
Klin Lab Diagn; 2021 May; 66(5):297-303. PubMed ID: 34047516
[TBL] [Abstract][Full Text] [Related]
2. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
3. The Detection of Stem-Like Circulating Tumor Cells Could Increase the Clinical Applicability of Liquid Biopsy in Ovarian Cancer.
Gening SO; Abakumova TV; Gafurbaeva DU; Rizvanov AA; Antoneeva II; Miftakhova RR; Peskov AB; Gening TP
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440558
[TBL] [Abstract][Full Text] [Related]
4. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
5. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
6. Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer.
Onuma T; Mizutani T; Fujita Y; Yamada S; Yoshida Y
J Trace Elem Med Biol; 2021 Dec; 68():126865. PubMed ID: 34601284
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS).
Farkas B; Boldizsar F; Bohonyi N; Farkas N; Marczi S; Kovacs GL; Bodis J; Koppan M
J Ovarian Res; 2020 Mar; 13(1):25. PubMed ID: 32138790
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
10. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
11. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
12. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.
Gastl G; Plante M; Finstad CL; Wong GY; Federici MG; Bander NH; Rubin SC
Br J Haematol; 1993 Mar; 83(3):433-41. PubMed ID: 8485049
[TBL] [Abstract][Full Text] [Related]
13. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
14. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
[TBL] [Abstract][Full Text] [Related]
15. Expression of IL-10 in patients with ovarian carcinoma.
Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
18. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
19. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
Naldini A; Morena E; Belotti D; Carraro F; Allavena P; Giavazzi R
Thromb Haemost; 2011 Oct; 106(4):705-11. PubMed ID: 21833453
[TBL] [Abstract][Full Text] [Related]
20. Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites.
Attar BM; Moore CM; George M; Ion-Nedelcu N; Turbay R; Zachariah A; Ramadori G; Fareed J; Van Thiel DH
World J Gastroenterol; 2014 Mar; 20(9):2374-82. PubMed ID: 24605035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
